FDA
-
-
-
-
-
-
-
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
-
-
-
-
-
-
-
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
-
-
-
-
-
-
-
Ocugen adds retina experts to advisory board, names new executives
-
-
-
-
-
-
-
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Di
-
-
-
-
-
-
-
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt
-
-
-
-
-
-
-
Ocugen (OCGN) Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial of OCU500
-
-
-
-
-
-
-
Ocugen (OCGN) Announces Removal of Clinical Hold on OCU200
-
328,151 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
